ZA201903747B - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Info

Publication number
ZA201903747B
ZA201903747B ZA2019/03747A ZA201903747A ZA201903747B ZA 201903747 B ZA201903747 B ZA 201903747B ZA 2019/03747 A ZA2019/03747 A ZA 2019/03747A ZA 201903747 A ZA201903747 A ZA 201903747A ZA 201903747 B ZA201903747 B ZA 201903747B
Authority
ZA
South Africa
Prior art keywords
alleviation
prevention
treatment
bipolar disorder
carbamate compounds
Prior art date
Application number
ZA2019/03747A
Other languages
English (en)
Inventor
Yu Jin Shin
Sei Myoung Han
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of ZA201903747B publication Critical patent/ZA201903747B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2019/03747A 2016-12-14 2019-06-11 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder ZA201903747B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
ZA201903747B true ZA201903747B (en) 2021-01-27

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/03747A ZA201903747B (en) 2016-12-14 2019-06-11 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28529A (id) * 1997-08-14 2001-05-31 Hoffmann La Roche Vinileter heterosiklik untuk gangguan neurologi
US6555585B2 (en) 2000-07-21 2003-04-29 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Also Published As

Publication number Publication date
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
AU2017374458A1 (en) 2019-07-04
ES3054693T3 (en) 2026-02-05
AU2017374458B2 (en) 2023-03-02
BR112019011930A2 (pt) 2019-10-29
US11571410B2 (en) 2023-02-07
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
CA3046297A1 (en) 2018-06-21
EP3556366B1 (en) 2025-10-22
CL2019001618A1 (es) 2019-08-23
RU2019121913A (ru) 2021-01-15
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
KR102635938B1 (ko) 2024-02-13
MX2019006940A (es) 2019-09-06
RU2019121913A3 (enExample) 2021-04-21
JP7208139B2 (ja) 2023-01-18
KR20190087572A (ko) 2019-07-24
CN110290788A (zh) 2019-09-27
EP3556366A1 (en) 2019-10-23
MY199104A (en) 2023-10-13
IL267195A (enExample) 2019-07-31

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
SI3600281T1 (sl) Kombinirana terapija za zdravljenje ali preprečevanje tumorjev
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
SI3109223T1 (sl) Zmes za obdelavo gnojil, ki vsebujejo sečnino
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
ZA201707951B (en) Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
IL263697A (en) Compounds, compositions and methods for prevention and/or treatment of cancer
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
SI3400269T1 (sl) Uporaba 4-bora-3a,4a-diaza-s-indacenov za varnostne namene
IL275573A (en) Methods and preparations for the treatment of hypercytokinemia and severe influenza or for their prevention
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
GB201408387D0 (en) Treatment of respiratory disorders
HUE051563T2 (hu) Gyógyszerkészítmény rák megelõzésére vagy kezelésére
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
PT3619204T (pt) Compostos para o tratamento de doenças respiratórias
IL253878A0 (en) An effective substance for the treatment of respiratory inflammation
LT3519050T (lt) Kompozicijos, skirtos oftalmologinių būklių gydymui
IL265976A (en) Use of a compound, pharmaceutical preparation and therapeutic method for the treatment or prevention of convulsions
IL252493B (en) Compounds for use in the prevention or treatment of cancer
DK3334425T3 (da) Methods of treatment or prevention of acute brain or nerve injuries
EP3284475A4 (en) Agent for prevention or treatment of corneal disorders